Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhuyin Li

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|August 18, 2020
Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fractionPrathap Kanagala, Jayanth R Arnold, Jamal N Khan, et al.
The Journal of Biological Chemistry|March 27, 2014
Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1Mindy I Davis, Stefan Gross, Min Shen, et al.
Physiological Genomics|February 25, 2020
Circulating and tissue matricellular RNA and protein expression in calcific aortic valve diseaseAlexander P Kossar, Wanda Anselmo, Juan B Grau, et al.
Nature Communications|February 6, 2015
Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacyHilary A Kenny, Madhu Lal-Nag, Erin A White, et al.
Bioorganic & Medicinal Chemistry|March 21, 2018
Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitorsJason M Rohde, Kyle R Brimacombe, Li Liu, et al.
Ebiomedicine|July 19, 2016
A Class of Diacylglycerol Acyltransferase 1 Inhibitors Identified by a Combination of Phenotypic High-throughput Screening, Genomics, and GeneticsKirsten Tschapalda, Ya-Qin Zhang, Li Liu, et al.
Therapeutic Advances in Endocrinology and Metabolism|July 17, 2019
Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetesGaurav S Gulsin, Prathap Kanagala, Daniel C S Chan, et al.
Science Translational Medicine|August 19, 2021
The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystoniaZachary F Caffall, Bradley J Wilkes, Ricardo Hernández-Martinez, et al.
JACC. Heart Failure|January 14, 2020
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to SpironolactoneJordana B Cohen, Sarah J Schrauben, Lei Zhao, et al.
Journal of the American College of Cardiology|March 21, 2020
Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection FractionJulio A Chirinos, Alena Orlenko, Lei Zhao, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|August 18, 2020
Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fractionPrathap Kanagala, Jayanth R Arnold, Jamal N Khan, et al.
The Journal of Biological Chemistry|March 27, 2014
Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1Mindy I Davis, Stefan Gross, Min Shen, et al.
Physiological Genomics|February 25, 2020
Circulating and tissue matricellular RNA and protein expression in calcific aortic valve diseaseAlexander P Kossar, Wanda Anselmo, Juan B Grau, et al.
Nature Communications|February 6, 2015
Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacyHilary A Kenny, Madhu Lal-Nag, Erin A White, et al.
Bioorganic & Medicinal Chemistry|March 21, 2018
Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitorsJason M Rohde, Kyle R Brimacombe, Li Liu, et al.
Ebiomedicine|July 19, 2016
A Class of Diacylglycerol Acyltransferase 1 Inhibitors Identified by a Combination of Phenotypic High-throughput Screening, Genomics, and GeneticsKirsten Tschapalda, Ya-Qin Zhang, Li Liu, et al.
Therapeutic Advances in Endocrinology and Metabolism|July 17, 2019
Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetesGaurav S Gulsin, Prathap Kanagala, Daniel C S Chan, et al.
Science Translational Medicine|August 19, 2021
The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystoniaZachary F Caffall, Bradley J Wilkes, Ricardo Hernández-Martinez, et al.
JACC. Heart Failure|January 14, 2020
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to SpironolactoneJordana B Cohen, Sarah J Schrauben, Lei Zhao, et al.
Journal of the American College of Cardiology|March 21, 2020
Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection FractionJulio A Chirinos, Alena Orlenko, Lei Zhao, et al.
Pageof 4